CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 161 enrolled
Drug / intervention
Regadenosondrug
Likely dose
Regadenoson 0.4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02130453
NCT02130453Phase 4Completed
CompareCT.gov

Use of Regadenoson for a Stress Echocardiogram Protocol Using Speckle Tracking Imaging

M.D. Anderson Cancer Center·interventional·Posted May 5, 2014·Updated Oct 2, 2024

In Brief

A Phase 4 clinical trial evaluating Regadenoson for Ischemia. Completed, enrolled 161 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to compare regadenoson nuclear stress testing with echocardiography strain measurements (an ultrasound imaging method that measures hearts function) in detecting coronary artery disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemia
CountriesUnited States
CollaboratorsAstellas Scientific & Medical Affairs, Inc.

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 5, 2014
Enrollment StartSep 30, 2014
Primary CompletionJun 28, 2024
TodayJul 2, 2026
Enrollment to primary: 9.7 yearsPosted 12.2 years ago

Interventions

Regadenosondrug

0.4 mg by vein given during nuclear stress testing with echocardiography strain measurements.